NASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $65.87 +0.95 (+1.46%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$66.54 +0.66 (+1.01%) As of 08:32 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Disc Medicine Stock (NASDAQ:IRON) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Disc Medicine alerts:Sign Up Key Stats Today's Range$64.05▼$66.2950-Day Range$64.92▼$82.6752-Week Range$40.00▼$99.50Volume784,081 shsAverage Volume513,380 shsMarket Capitalization$252.28 millionP/E RatioN/ADividend YieldN/APrice Target$110.18Consensus RatingModerate Buy Company Overview Disc Medicine, Inc. (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. The company’s research centers on disorders involving red blood cell production, iron metabolism and related biological pathways, with the goal of addressing conditions that often have limited treatment options. Disc Medicine’s lead product candidate is bitopertin, an oral small-molecule inhibitor of glycine transporter 1. The company is evaluating bitopertin in diseases including erythropoietic protoporphyria, a rare disorder characterized by abnormal accumulation of protoporphyrin that can cause severe sensitivity to sunlight. Its pipeline also includes DISC-0974, an investigational antibody designed to target hemojuvelin and regulate hepcidin, a hormone involved in iron metabolism, for potential use in anemia associated with chronic disease and other hematologic conditions. Founded in 2017, Disc Medicine is headquartered in Waltham, Massachusetts. The company’s programs are in clinical development and are being evaluated through studies conducted in the United States and other regions. Disc Medicine is led by John Quisel, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Disc Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreIRON MarketRank™: Disc Medicine scored higher than 50% of companies evaluated by MarketBeat, and ranked 531st out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingDisc Medicine has received a consensus rating of Moderate Buy. The company's average rating score is 2.77, and is based on no strong buy ratings, 11 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialDisc Medicine has a consensus price target of $110.18, representing about 67.3% upside from its current price of $65.87.Amount of Analyst CoverageDisc Medicine has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($6.61) to ($7.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -10.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -10.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 3.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.51% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 13.63, which indicates bearish sentiment.Change versus previous monthShort interest in Disc Medicine has recently decreased by 2.14%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.51 News SentimentDisc Medicine has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.74 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Disc Medicine this week, compared to 8 articles on an average week.Search Interest3 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,721,690.00 in company stock.Percentage Held by Insiders3.76% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRON Stock News HeadlinesDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 28 at 3:02 PM | globenewswire.comROSEN, A LONGSTANDING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONSeptember 27 at 3:11 PM | markets.businessinsider.com"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.September 30 at 1:00 AM | SmartAsset (Ad)Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRONSeptember 26, 2026 | prnewswire.comDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 25, 2026 | globenewswire.comDisc Medicine Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 22, 2026 | globenewswire.comKevin Bitterman Sells 1,689 Shares of Disc Medicine (NASDAQ:IRON) StockSeptember 10, 2026 | insidertrades.comKevin Bitterman Sells 129 Shares of Disc Medicine (NASDAQ:IRON) StockSeptember 4, 2026 | insidertrades.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $79.41 at the start of the year. Since then, IRON stock has decreased by 17.1% and is now trading at $65.87. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) announced its quarterly earnings results on Thursday, July, 30th. The company reported ($1.54) EPS for the quarter, topping analysts' consensus estimates of ($1.71) by $0.17. When did Disc Medicine IPO? Disc Medicine (IRON) raised $105 million in an initial public offering on Wednesday, August 12th 2020. The company issued 10,500,000 shares at $10.00 per share. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings7/30/2026Today9/30/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 For the last 2 weeks, IRON's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IRON CIK1816736 Webwww.discmedicine.com Phone(617) 674-9274FaxN/AEmployees165Year Founded2017Price Target and Rating Average Price Target for Disc Medicine$110.18 High Price Target$153.00 Low Price Target$83.00 Potential Upside/Downside+67.3%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($6.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$212.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.17% Return on Assets-33.65% Debt Debt-to-Equity Ratio0.09 Current Ratio24.14 Quick Ratio24.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$19.52 per share Price / Book3.37Miscellaneous Outstanding Shares3,830,000Free Float36,949,000Market Cap$252.28 million OptionableNot Optionable Beta0.97 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IRON) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersDr. Ron Paul Issues New Warning: “The Next Financial Crisis Is Here”Dr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
